UK – NICE u-turn backs NHS use of Veltassa

The National Institute for Health and Care Excellence has given its stamp of approval for NHS use of Vifor Pharma’s hyperkalaemia drug Veltassa (patiromer).

The drug, which was initially turned down by the cost regulator in 2018, will be offered as an option for adults in emergency care or for people with chronic hyperkalaemia and may benefit 13,600 people.

Hyperkalaemia is characterised by elevated potassium levels in the blood. Risk of developing the condition increases significantly for patients with chronic kidney disease and for those who take life-saving medications for heart failure, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, which can increase potassium in the blood…